JP2024519487A5 - - Google Patents
Info
- Publication number
- JP2024519487A5 JP2024519487A5 JP2023567930A JP2023567930A JP2024519487A5 JP 2024519487 A5 JP2024519487 A5 JP 2024519487A5 JP 2023567930 A JP2023567930 A JP 2023567930A JP 2023567930 A JP2023567930 A JP 2023567930A JP 2024519487 A5 JP2024519487 A5 JP 2024519487A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163185608P | 2021-05-07 | 2021-05-07 | |
| US63/185,608 | 2021-05-07 | ||
| PCT/US2022/027262 WO2022235558A1 (en) | 2021-05-07 | 2022-05-02 | Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2024519487A JP2024519487A (ja) | 2024-05-14 |
| JP2024519487A5 true JP2024519487A5 (https=) | 2024-06-05 |
| JPWO2022235558A5 JPWO2022235558A5 (https=) | 2024-06-05 |
| JP7846132B2 JP7846132B2 (ja) | 2026-04-14 |
Family
ID=83932809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023567930A Active JP7846132B2 (ja) | 2021-05-07 | 2022-05-02 | Ｎａｖ１．８阻害薬としてのアリール ３－オキソピペラジンカルボキサミド類及びヘテロアリール ３－オキソピペラジンカルボキサミド類 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240246932A1 (https=) |
| EP (1) | EP4334306A4 (https=) |
| JP (1) | JP7846132B2 (https=) |
| KR (1) | KR20240006606A (https=) |
| CN (1) | CN117597339A (https=) |
| AU (1) | AU2022270061B2 (https=) |
| BR (1) | BR112023023186A2 (https=) |
| CA (1) | CA3217605A1 (https=) |
| MX (1) | MX2023013147A (https=) |
| WO (1) | WO2022235558A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025513452A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| UY40234A (es) | 2022-04-22 | 2023-11-15 | Vertex Pharma | Compuestos heteroarilo para el tratamiento del dolor |
| GEAP202516634A (en) | 2022-04-22 | 2025-02-25 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
| AU2023257313A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| AU2023391870A1 (en) | 2022-12-06 | 2025-06-05 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025122953A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007002410A (es) * | 2004-08-30 | 2007-05-07 | Neuromed Pharmaceuticals Ltd | Derivados de urea como bloqueadores de canal de calcio. |
| US7767680B2 (en) * | 2004-11-03 | 2010-08-03 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| JP5361857B2 (ja) * | 2007-03-23 | 2013-12-04 | ファイザー・リミテッド | イオンチャネルの阻害剤 |
| WO2011026240A1 (en) * | 2009-09-04 | 2011-03-10 | Zalicus Pharmaceuticals Ltd. | Oxopiperazine derivatives for the treatment of pain and epilepsy |
| EP3873893A1 (en) * | 2018-11-02 | 2021-09-08 | Merck Sharp & Dohme Corp. | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
| GEP20257750B (en) * | 2020-06-17 | 2025-03-25 | Merck Sharp & Dohme Llc | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors |
| JP2023530319A (ja) * | 2020-06-17 | 2023-07-14 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｎａｖ１．８阻害剤としての２－オキソ－オキサゾリジン－５－カルボキサミド |
| BR112022024476A2 (pt) * | 2020-06-17 | 2022-12-27 | Merck Sharp & Dohme Llc | 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8 |
| EP4334293A1 (en) * | 2021-05-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
-
2022
- 2022-05-02 MX MX2023013147A patent/MX2023013147A/es unknown
- 2022-05-02 US US18/557,667 patent/US20240246932A1/en active Pending
- 2022-05-02 AU AU2022270061A patent/AU2022270061B2/en active Active
- 2022-05-02 EP EP22799359.9A patent/EP4334306A4/en active Pending
- 2022-05-02 BR BR112023023186A patent/BR112023023186A2/pt unknown
- 2022-05-02 CA CA3217605A patent/CA3217605A1/en active Pending
- 2022-05-02 CN CN202280047884.9A patent/CN117597339A/zh active Pending
- 2022-05-02 KR KR1020237042102A patent/KR20240006606A/ko active Pending
- 2022-05-02 JP JP2023567930A patent/JP7846132B2/ja active Active
- 2022-05-02 WO PCT/US2022/027262 patent/WO2022235558A1/en not_active Ceased